Expert gastroenterologists examine the sequencing of therapies and optimizing treatment selection in the evolving treatment landscape for ulcerative colitis.
May 31st 2022
David P. Hudesman, MD, and Marla Dubinsky, MD, define symptoms and potential disease triggers for inflammatory bowel disease (IBD).
Ellen J. Scherl, MD, highlights the different subtypes of ulcerative colitis and the differential diagnosis with Crohn’s disease.
June 7th 2022
Drs David P. Hudesman, Marla Dubinsky, and Ellen J. Scherl explore the impact of IBD and ulcerative colitis on a patient’s quality of life.
Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.
June 14th 2022
Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.
David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.
June 21st 2022
Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.
David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.
Noah Rindos, MD, Talks Fibroids, Adenomyosis and Pregnancy
Kausik Ray, MD: A Risk-Based Look at LDL Cholesterol Lowering
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy